Non-α-biased IL-2 enhances both intratumoral and subcutaneous CpG/α-OX40 therapy, unleashing systemic antitumor immunity in mice
Kejie Huang, Xiaobo Ding, Xuehuan Wen, Chaoming Huang, Yan Chen, Xujie Zhou, Leying Zhou, Yi He, Zhixiang Bai, Chunhong Zhang, Yi Jin, Jianmin Li, Zhenghua Fei, Wenfeng Li, Chen Chen · 2025
Read Non-α-biased IL-2 enhances both intratumoral and subcutaneous CpG/α-OX40 therapy, unleashing systemic antitumor immunity in mice by Kejie Huang, Xiaobo Ding, Xuehuan Wen, Chaoming Huang, Yan Chen, Xujie Zhou, Leying Zhou, Yi He, Zhixiang Bai, Chunhong Zhang, Yi Jin, Jianmin Li, Zhenghua Fei, Wenfeng Li, Chen Chen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12742144.txt.
Description
Kejie Huang and co-authors boost a cancer vaccine strategy with a redesigned immune signal in this 2025 mouse study. The vaccine pairs two agents injected at the tumor, and it works in hot tumors but fails in cold ones crowded with suppressor cells. The team added a form of interleukin-2 tuned to avoid one receptor type.
In breast and colon cancer models, the triple mix slowed both treated and distant tumors and cut lung spread. Given under the skin, it wiped out colon tumors in over half the mice and left lasting protection. Killer T cells grew stronger while suppressor cells weakened. The authors offer the mix as a candidate for hard-to-treat cancers.
Catalog record
| CREATOR | Kejie Huang, Xiaobo Ding, Xuehuan Wen, Chaoming Huang, Yan Chen, Xujie Zhou, Leying Zhou, Yi He, Zhixiang Bai, Chunhong Zhang, Yi Jin, Jianmin Li, Zhenghua Fei, Wenfeng Li, Chen Chen |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |